Interpace Biosciences (IDXG) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Voting matters and shareholder proposals
Ratification of EisnerAmper, LLP as independent registered public accounting firm for fiscal year ending December 31, 2024 is up for shareholder vote.
Shareholders may transact other business as may properly come before the meeting or any adjournments.
Audit committee and external auditor matters
EisnerAmper, LLP is recommended for ratification as the external auditor for the upcoming fiscal year.
Shareholder rights and capital structure
Multiple share classes are represented for voting, including Common, Class A through F, and 401K shares.
Shareholders are encouraged to vote virtually or by proxy before the annual meeting date.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Interpace Biosciences
- Virtual annual meeting to ratify EisnerAmper as auditor; Series B holders retain key voting rights.IDXG
Proxy Filing2 Dec 2025 - Record thyroid test volumes and $8.8M revenue mark Q3 amid PancraGEN® discontinuation.IDXG
Q3 202512 Nov 2025 - Record Q2 2024 revenue and profit growth achieved amid ongoing regulatory risks.IDXG
Q2 20248 Oct 2025 - Record thyroid test growth offsets some losses as PancraGEN® exit drives revenue decline.IDXG
Q2 20257 Aug 2025 - Record revenue, profitability, and test volume drive growth and support Nasdaq uplisting plans.IDXG
Q3 202413 Jun 2025 - 2024 revenue rose 17% and net income more than tripled, but PancraGEN® coverage loss poses major risk.IDXG
Q4 20249 Jun 2025 - Double-digit revenue growth and record thyroid tests offset PancraGEN®'s Medicare loss and restructuring.IDXG
Q1 20256 Jun 2025